| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.1 | 0.08 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.08 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | -0.061 | 0.08 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.08 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.05 | 0.08 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.096 | 0.09 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.056 | 0.09 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.09 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.09 |